Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Decrease in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant decrease in short interest in January. As of January 15th, there was short interest totaling 58,591 shares, a decrease of 38.7% from the December 31st total of 95,551 shares. Approximately 2.5% of the company’s stock are short sold. Based on an average daily volume of 352,079 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 352,079 shares, the short-interest ratio is currently 0.2 days. Approximately 2.5% of the company’s stock are short sold.

Analysts Set New Price Targets

Several brokerages recently issued reports on VRAX. HC Wainwright reissued a “buy” rating and issued a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Friday, January 9th. Finally, Zacks Research upgraded shares of Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Stock Down 1.7%

VRAX opened at $0.29 on Friday. Virax Biolabs Group has a fifty-two week low of $0.26 and a fifty-two week high of $2.29. The business has a 50-day moving average of $0.38 and a 200-day moving average of $0.57.

Virax Biolabs Group (NASDAQ:VRAX) last announced its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The company had revenue of $0.00 million during the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.